mTORC1 promotes cell growth and proliferation — the same activity that makes it a longevity target makes its hyperactivation a cancer risk. The clearest proof-of-concept is tuberous sclerosis complex, a genetic disorder where losing the TSC1/TSC2 brake leaves mTORC1 stuck permanently "on" and drives tumor growth — and where an mTOR inhibitor (everolimus) is a direct, FDA-approved treatment. mTOR inhibitors are also approved treatments in kidney cancer, hormone-resistant breast cancer, and pancreatic neuroendocrine tumors.
The genetic proof of concept: tuberous sclerosis complex
FRA2013B — a phase 3 RCT (n=117) in TSC — the disease where mTOR is stuck "on" by a genetic fault — showed everolimus shrinks SEGA brain tumors by ≥50% in 35% of patients versus far fewer on placebo.
BIS2013B — the companion phase 3 RCT (n=118) targeting kidney tumors (angiomyolipomas) in the same disease: everolimus shrank them by ≥50% in 42% of patients.
GAO2026BB — in a multicenter cohort of 183 TSC-associated renal angiomyolipoma patients, everolimus reduced tumor volume by ≥50% in 44% of patients at 3 months, rising further with continued treatment.
TSC matters because it isolates mTOR as the cause, not just a correlate — the tumors exist specifically because mTORC1 can't be switched off, and switching it off pharmacologically shrinks them.
Sporadic cancers where mTOR signaling gets switched on
BAS2012B — in hormone-receptor-positive advanced breast cancer, resistance to endocrine therapy is partly driven by mTOR signaling switching on; adding everolimus to endocrine therapy roughly doubled progression-free survival in a phase 3 RCT (n=724).
HUD2007B — in poor-prognosis metastatic kidney cancer, temsirolimus (a rapalog) extended median overall survival to 10.9 vs 7.3 months over standard interferon therapy.
YAO2011B — in pancreatic neuroendocrine tumors, everolimus more than doubled progression-free survival (11.0 vs 4.6 months) in a phase 3 RCT (n=410), making it a standard treatment for this cancer.
The double-edged-sword problem for longevity research
This is exactly why mTOR inhibition is scientifically interesting for aging, not just cancer: a pathway that drives unwanted growth when stuck "on" is a plausible target for slowing the growth-related decline of aging when partially turned down. But it also means any long-term, population-wide use of mTOR inhibitors for healthy aging needs to reckon with a drug class whose clearest, best-proven human benefit so far is in treating cancers that mTOR hyperactivation helps drive.
